EUVIMEDEUVIMED entdecken
Crossref

PDL1/HER2‐Targeted Lipid‐Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2 + Breast Cancer Immunotherapy

Jilai Tian iD, Shixiao Wan, Zhen Yang, Mengting Wang, Wenzhao Zhou, Guanqun Wo, Shuping Fu, Shiya Zheng, Gaoxin Zhou, Xiaomin Hu, Yichen Guo, Jun Guo iD

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202400030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Jilai Tian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, P. R. China. Hauptthemen laut MEDLINE: Photochemotherapy, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed death (PD) 1/PD ligand 1 (PDL1) inhibitors are immune checkpoint inhibitors (ICIs) that may facilitate HER2‐positive breast cancer treatment; however, their clinical efficacy remains elusive. Oxygen‐enhanced photodynamic therapy (PDT) increases immunogenic cell death (ICD), providing a promising strategy to render the tumor microenvironment more sensitive to the ICIs. Lipid‐encapsulated oxygen nanobubbles (Lipo‐NBs‐O 2 ) obtained using nanobubbles (NBs) water for oxygen delivery in vivo can facilitate enhanced PDT. Here, dual‐receptor targeted Lipo‐NBs‐O 2 (DRT@Lipo‐NBs‐O 2 ) is prepared by modifying Lipo‐NBs‐O 2 with anti‐PDL1 scFv and the fusion protein anti‐HER2 scFv‐tandem‐repeat cytochrome c (anti‐HER2‐nCyt c ). Copper phthalocyanine is the photosensitizer (PS). DRT@Lipo‐PS‐NBs‐O 2 plus near‐infrared irradiation leads to robust ICD induction, increasing DC activation and CD8 + T‐cell numbers. Modification with anti‐PDL1 scFv improves tumor distribution of DRT@Lipo‐PS‐NBs‐O 2 and plays the ICI role, invigorating CD8 + T cells and boosting the effects of immunotherapy. Oxygen supplied through DRT@Lipo‐PS‐NBs‐O 2 reduces P‐glycoprotein expression. Enhanced PDT and Cyt c can cause tumor cell death, thereby reducing the immune burden. Under dual receptor targeting and laser local irradiation, tumor cells become subject to the combination effects of PDT, ICD, ICIs, and apoptosis; this effectively suppresses tumor growth and metastasis. Lipo‐NBs‐O 2 affords a combination of oxygen delivery and multidrug therapy to alleviate HER2‐positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyErb-b2 Receptor Tyrosine KinasesBreast NeoplasmsB7-H1 AntigenImmunotherapyOxygenLipidsAnimalsFemaleMiceHumansCell Line, TumorPhotosensitizing AgentsMice, Inbred BALB CNanoparticles

Stichwörter der Autor:innen

dual‐receptor targetimmune checkpoint inhibitorimmunogenic cell deathoxygen nanobubblephotodynamic therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesB7-H1 AntigenOxygenLipidsPhotosensitizing AgentsERBB2 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, P. R. China.
  • Department of Integrated Chinese and Western Medicine, School of Chinese Medicine & School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China.
  • Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, P. R. China.
  • Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, P. R. China.
  • School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, 211166, P. R. China.
  • OriGene Technologies Inc. at Wuxi, Jiangsu, 214000, P. R. China.

ORCID-Profile: Jilai Tian, Jun Guo

Förderung

  • National Natural Science Foundation of China
  • Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine

Zitieren

APA

Tian, J., Wan, S., Yang, Z., Wang, M., Zhou, W., Wo, G., Fu, S., Zheng, S., Zhou, G., Hu, X., Guo, Y., & Guo, J. (2024). PDL1/HER2‐Targeted Lipid‐Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2 + Breast Cancer Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400030

Vancouver

Tian J, Wan S, Yang Z, Wang M, Zhou W, Wo G, et al. PDL1/HER2‐Targeted Lipid‐Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2 + Breast Cancer Immunotherapy. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400030

BibTeX
@article{Tian2024,
  author = {Tian, Jilai and Wan, Shixiao and Yang, Zhen and Wang, Mengting and Zhou, Wenzhao and Wo, Guanqun and Fu, Shuping and Zheng, Shiya and Zhou, Gaoxin and Hu, Xiaomin and Guo, Yichen and Guo, Jun},
  title = {PDL1/HER2‐Targeted Lipid‐Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2 + Breast Cancer Immunotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202400030}
}
Kostenlos starten →